Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dichloroacetic Acid
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Saol Therapeutics Announces Major Clinical Milestones Across Multiple Development Programs
Details : SL1009 is a sodium dichloroacetate, which inhibits PDK to stimulate residual PDC activity and ATP production by mitochondria. It is being investigated for pyruvate dehydrogenase complex deficiency.
Product Name : SL1009
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 17, 2025
Lead Product(s) : Dichloroacetic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dichloroacetic Acid
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Saol’s SL1009 NDA for Pyruvate Dehydrogenase Deficiency Accepted
Details : SL1009 is a sodium dichloroacetate, which inhibits PDK to stimulate residual PDC activity and ATP production by mitochondria. It is being investigated for pyruvate dehydrogenase complex deficiency.
Product Name : SL1009
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 28, 2025
Lead Product(s) : Dichloroacetic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dichloroacetic Acid
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Saol Submits NDA to FDA for SL1009 in Undisclosed Indication
Details : SL1009 is a Sodium Dichloroacetate, which inhibits PDK to stimulate residual PDC activity and ATP production by mitochondria. It is being investigated for pyruvate dehydrogenase complex deficiency.
Product Name : SL1009
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 03, 2024
Lead Product(s) : Dichloroacetic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SL-1002
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Saol Therapeutics Shares Positive SL-1002 Results for Limb Spasticity
Details : SL-1002 is a novel, chemoneurolytic injection, that utilizes Saol's proprietary CYCLOPHLEX™ technology, which is investigated for the treatment of Limb Spasticity.
Product Name : SL-1002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2024
Lead Product(s) : SL-1002
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SL-1002
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SL-1002 is a novel, chemoneurolytic injection, that utilizes Saol's proprietary CYCLOPHLEX™ technology, which is investigated for the treatment of Osteoarthritis Knee Pain.
Product Name : SL-1002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2023
Lead Product(s) : SL-1002
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Baclofen
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Amneal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Amneal Acquires Saol Therapeutics’ Baclofen Franchise
Details : Amneal is adding Saol’s experienced institutional commercial team for Lioresal that can be utilized to support product launches, including biosimilar products, filgrastim (biosimilar for Neupogen), pegfilgrastim (biosimilar for Neulasta) & bevacizumab ...
Product Name : Lioresal
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 01, 2022
Lead Product(s) : Baclofen
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Amneal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Dichloroacetic Acid
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dichloroacetate (SL-1009) has the potential to be the 1st approved medication for the mitochondrial disease PDCD. DCA inhibits PDKs to stimulate residual PDC activity and increase energy (ATP) production by mitochondria.
Product Name : SL-1009
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2022
Lead Product(s) : Dichloroacetic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Cytomegalovirus Immune Globulin,Ganciclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Kamada
Deal Size : $145.0 million
Deal Type : Acquisition
Details : Under the terms of the agreement, Kamada Inc., will be responsible for the commercialization of the CYTOGAM®, WINRHO®, HEPAGAM B®, and VARIZIG® in the U.S., including direct sales to wholesalers and local distributers.
Product Name : Cytogam
Product Type : Protein
Upfront Cash : $95.0 million
November 22, 2021
Lead Product(s) : Human Cytomegalovirus Immune Globulin,Ganciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Kamada
Deal Size : $145.0 million
Deal Type : Acquisition